Loading...
This is another report from the discontinued arm of the WHI's hormone therapy trial (Journal Watch Women's Health Aug 7 2002 ). In this arm of the trial, 16,608 women were randomly assigned to receive either placebo or conjugated estrogens (0.625 mg/day) plus medroxyprogesterone acetate (2.5 mg/day).
This arm was discontinued in part because HT recipients showed an increased risk for breast cancer. WHI researchers now take a detailed look at this increased risk.
Mammograms and clinical breast exams were performed at baseline and annually thereafter. During a mean follow-up of 5.6 years, the total number of incident breast cancers was significantly higher in the HT group than in the placebo group (hazard ratio, 1.24), as was the number of inva…